# Telix Pharmaceuticals Limited share price today (Telix Pharmaceuticals Limited, TLX)

> Telix Pharmaceuticals Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TLX · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/tlx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $9.42 (−3.0% in a year)
- P/E: 98.6×, over 1 year
- Revenue (Jun 2026): $477 M (+22.3% on a year ago)
- Profit (Jun 2026): $38.3 M
- Operating margin: 9.7% (+7.0 points on a year ago)
- ROE: −2%, FY25
- ROIC: 6.8%, against a 6.5% cost of capital: +0.3 points
- Profit that came in as cash: 167%, last 3 years

The main question: the share price moved −3.0% in a year while yearly earnings per share moved −121.6%. The difference came from the market paying a higher multiple. ## What is the Telix Pharmaceuticals Limited share price today? Telix Pharmaceuticals Limited's share price was $9.42 at the close on 5 November 2026. It has been moving sideways for 1 week. That is 5.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between $7 and $13, and at that close it sat 48% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 6 weeks running. Over the last 2 years the share price moved −37% while the S&P 500 moved +25%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Telix Pharmaceuticals Limited pay? Telix Pharmaceuticals Limited pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Telix Pharmaceuticals Limited on? Telix Pharmaceuticals Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Telix Pharmaceuticals Limited profitable? Telix Pharmaceuticals Limited earned $38.3 M of net profit in the Jun 2026 quarter. The full FY25 year was a loss of $7.1 M. That is 8.0% of the quarter's revenue. The same quarter a year earlier earned $19.6 M. 8 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was −$7.1 M (−121.2% on the year before). On average over the last four quarters, profit changed −80.0% and revenue +44.7%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Telix Pharmaceuticals Limited make, and is it growing? Telix Pharmaceuticals Limited reported $477 M of revenue in the Jun 2026 quarter, +22.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 247.3% a year on average. The last full year, FY25, came in at $804 M. FY25 revenue was $804 M, +55.6% on the year before. Recent pace: the last four quarters grew +44.7% on average, against 247.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +132.2%, against +688.5% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Telix Pharmaceuticals Limited keep? Telix Pharmaceuticals Limited's operating margin was 9.7% in the Jun 2026 quarter, 7.0 percentage points higher than the same quarter a year ago. Over the last four quarters it has moved −2.7 percentage points. Across 6 years it has been between −1,069.6% and 10.8%. The latest quarter is within that range. Why the margin moved: operating margin changed −2.7 percentage points on the year while gross margin changed −13.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Telix Pharmaceuticals Limited's profit turning into cash? Over the last 3 years, 167% of Telix Pharmaceuticals Limited's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 its operations used $17.3 M of cash, against −$7.1 M of profit. After $25.7 M of spending on assets, free cash was −$43.0 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Telix Pharmaceuticals Limited's cash go? Telix Pharmaceuticals Limited does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $41.1 M on assets over the last 3 years. Averaged over those years that is 1.7% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $41.1 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Telix Pharmaceuticals Limited's P/E ratio, and how does it compare with its own history? Telix Pharmaceuticals Limited's P/E is 98.6×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −121.6% while the price moved −3.0%. The price did better than earnings, which pushed the multiple up within its own range. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Telix Pharmaceuticals Limited business getting better or worse? Telix Pharmaceuticals Limited's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Telix Pharmaceuticals Limited earn on its capital? Telix Pharmaceuticals Limited earned a ROE of −2% in FY25. That is up from a low of −3,731% in FY21. Its return on capital used (ROIC) is 0.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a −0.9% net margin and 0.69× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −0.9% net margin × 0.69× asset turnover × 2.80× leverage (assets divided by equity) ≈ −1.7% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 6.8% − 6.5% = +0.3 percentage points. The 6.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 6.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 3.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Telix Pharmaceuticals Limited have too much debt? Telix Pharmaceuticals Limited has total debt of $580 M against shareholder equity of $488 M as of Jun 2026, so its debt is 1.19× its equity. Year by year, that ratio went from 1.18 in FY21 to 1.12 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Telix Pharmaceuticals Limited shareholding pattern? We have no ownership or short-position figures for Telix Pharmaceuticals Limited, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 0.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Telix Pharmaceuticals Limited from balance-sheet trouble? For Telix Pharmaceuticals Limited, the Z-score is 3.19. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.19 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Telix Pharmaceuticals Limited rank in its industry? There is no score against its industry: Telix Pharmaceuticals Limited is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Telix Pharmaceuticals Limited compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Telix Pharmaceuticals Limited in size? Telix Pharmaceuticals Limited is the 56th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Tango Therapeutics, Inc., Iovance Biotherapeutics, Inc. and Arcutis Biotherapeutics, Inc. Just below it: Tarsus Pharmaceuticals, Inc., Viridian Therapeutics, Inc. and Denali Therapeutics Inc. ### Biotechnology companies close in size

1. [Tango Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tngx) $3.5 billion
2. [Iovance Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/iova) $3.5 billion
3. [Arcutis Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/arqt) $3.4 billion
4. Telix Pharmaceuticals Limited $3.3 billion
5. [Tarsus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/tars) $3.3 billion
6. [Viridian Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/vrdn) $3.2 billion
7. [Denali Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/dnli) $3.2 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Liberty Global Ltd.](https://www.sectoralpha.in/us/stocks/lbtya) $3.2 billion · Telecom Services
2. [Cal-Maine Foods, Inc.](https://www.sectoralpha.in/us/stocks/calm) $3.2 billion · Farm Products
3. Telix Pharmaceuticals Limited $3.2 billion
4. [FS KKR Capital Corp.](https://www.sectoralpha.in/us/stocks/fsk) $3.2 billion · Asset Management
5. [Kyivstar Group Ltd.](https://www.sectoralpha.in/us/stocks/kyiv) $3.2 billion · Telecom Services

## What else do people ask about Telix Pharmaceuticals Limited? ### What were Telix Pharmaceuticals Limited Limited's latest quarterly results? Telix Pharmaceuticals Limited reported revenue of $477 M and net profit of $38.3 M for the Jun 2026 quarter. Earnings per share were $0.11. The operating margin was 9.7%, 7.0 percentage points higher than a year earlier (as of 5 November 2026). ### What is Telix Pharmaceuticals Limited Limited's market cap? Telix Pharmaceuticals Limited's market capitalisation is $3.3 B at a stock price of $9.42. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Telix Pharmaceuticals Limited Limited performing? Telix Pharmaceuticals Limited's share price has been moving sideways for 1 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 6 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Telix Pharmaceuticals Limited Limited's stock price go up? This page does not forecast Telix Pharmaceuticals Limited's stock price. What it shows instead: the stock price is $9.42, and it has been moving sideways for 1 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Telix Pharmaceuticals Limited Limited in its business cycle? Telix Pharmaceuticals Limited's FY25 operating margin was 2.4%, against a 6-year range of −1,069.6% to 10.8%: the middle of its own range, neither a peak nor a low. The latest quarter was 9.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Telix Pharmaceuticals Limited Limited story? The main question: the share price moved −3.0% in a year while yearly earnings per share moved −121.6%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Telix Pharmaceuticals Limited Limited a stock worth studying right now? What the numbers show: Telix Pharmaceuticals Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.